Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Deutsches Krebsforschungszentrum

Julien Lefranc

Benjamin Bader

Philip Lienau

Antje Margret Wengner

Marcus Koppitz

Gerhard Siemeister

Hans Briem

Knut Eis

Ulrich Lücking

Hans Schick

Wilhelm Bone

Lars Wortmann

Joanna Grudzinska-Goebel

Dieter Moosmayer

Uwe Eberspächer

Detlef Stöckigt

Ulf Bömer

Ludwig Zorn

Ulrich Klar

Dirk Kosemund

Franz Von Nussbaum

Norbert Schmees

Judith Günther

Michael Platten

Lars Röse

Ulrike Röhn

Anne Mengel

Detlev Sülzle

Volker Schulze

Ursula Mönning

Ilona Gutcher

Georg Kettschau

Clara Christ

Kirstin Petersen

Keith Graham

Tobias Heinrich

Jens Schröder

Nicole Schmidt

Horst Irlbacher

Roman Hillig

Anja Giese

Joszef Bálint

Florian Prinz

Ulrich Lucking

Uwe Eberspacher

Hans (deceased) Schick

Hans (deseased) Schick

Hassan Y Harb

Ashley Eheim

Antje-Margret Wengner

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.

2-(morpholin-4-yl)-1,7-naphthyridines

The present invention covers 2-phenylpyrimidine-4-carboxamide compounds of general formula (I): (I) 5 in which X, Y, Z, R1, R2, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

2-phenylpyrimidine-4-carboxamides as AHR inhibitors

The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients. 

2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R, R, R, Rand Rare as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients. 

Heteroarylbenzimidazole compounds

The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines

The present invention relates to substituted pyrazolopyridinamine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, inflammatory disease and disease associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitors

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

Growing community of inventors

Berlin, Germany

Julien Lefranc